The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bayer
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
 
Erika Paige Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); BerGenBio (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Orinove (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Unum Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro
 
Mafalda Oliveira
Honoraria - Novartis; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Puma Biotechnology; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Celldex (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Philips Healthcare (Inst); Piqur (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Eisai; GP Pharm; Grunenthal; Novartis; Pierre Fabre; Roche
 
Udai Banerji
Employment - Institute of Cancer Research
Honoraria - Astellas Pharma; Lilly
Consulting or Advisory Role - Boehringer Ingelheim; Janssen; Novartis; Phoenix Solutions
Research Funding - AstraZeneca (Inst); BTG (Inst); Chugai Pharma (Inst); Onyx (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bayer; Sierra Oncology
 
Cristina Hernando
No Relationships to Disclose
 
Javier Garcia-Corbacho
No Relationships to Disclose
 
Anne Armstrong
No Relationships to Disclose
 
Eva Ciruelos
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
 
Manish R. Patel
Honoraria - Bayer; Genentech; Janssen Oncology; Pfizer; Pharmacyclics
Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); CicloMed (Inst); Clovis Oncology (Inst); Curis (Inst); cyteir (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kyocera (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Placon (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PubGene (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Vigeo Therapeutics (Inst); Xencor (Inst)
 
Jason Incorvati
No Relationships to Disclose
 
Chris Twelves
No Relationships to Disclose
 
Tim Brier
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Danielle Carroll
Employment - AstraZeneca/MedImmune; Azeria therapeutics (I)
Leadership - Azeria Therapeutics (I)
Stock and Other Ownership Interests - AstraZeneca/MedImmune; Azeria Therapeutics (I)
Honoraria - AstraZeneca (I)
Consulting or Advisory Role - Azeria Therapeutics (I)
Research Funding - AstraZeneca (I)
Patents, Royalties, Other Intellectual Property - Patent: Anti-cxc chemokine receptor-2 binding molecules and uses thereof; Patent: Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia; Royalties from Active Motif (I)
 
Steven Fox
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Teresa Klinowska
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Justin P O Lindemann
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Richard Mather
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Rhiannon Maudsley
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Sam McGuinness
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Andy Sykes
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Richard Baird
No Relationships to Disclose